Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer
- 212 Downloads
The objective of this study was to evaluate the correlation between 25-OH vitamin D and ovarian cancer as a diagnostic marker or recurrence disease marker. We studied the following: (1) 61 women without gynecologic diseases, (2) 45 women affected by benign ovarian disease, (3) 46 women with recent diagnosis of ovarian cancer, (4) 26 follow-up women with recurrent ovarian cancer, and (5) 32 follow-up women with stable ovarian cancer. The 25-OH vitamin D was quantified with LUMIPULSE® G 25-OH vitamin D on LUMIPULSE® G 1200 (Fujirebio, Japan). As a threshold value, identified by ROC curve analysis, 20.2 ng/mL (sensitivity 73.3 %, specificity 84 %) was chosen corresponding to the limit between sufficient and insufficient 25-OH vitamin D according to the WHO. Low 25-OH vitamin D levels were observed in 26 % of women without gynecologic diseases, in 80 % of women with recent diagnosis of ovarian cancer and in 24 % women affected by benign ovarian diseases (p < 0.001). The follow-up study showed an insufficient level of 25-OH vitamin D in 73 % women with recurrent ovarian cancer and in 47 % women with stable ovarian cancer (p < 0.0003). This study showed that patients with ovarian cancer are often insufficient in 25-OH vitamin D compared to women with benign ovarian diseases. The women with recurrent ovarian cancer presented more often low levels compared to women with stable ovarian cancer. This study suggests that 25-OH vitamin D, due to its antiproliferative properties, can be a good marker for ovarian cancer also.
Keywords25-OH vitamin D Biomarker Epithelial ovarian cancer Follow-up
This study is founded by the University of Rome Sapienza. The authors are thankful to Giuseppina Gennarini, Barbara Colaprisca, and Silvestra Tudini for their excellent technical assistance.
Conflicts of interest
- 2.Li K, Hüsing A, Fortner RT, Tjønneland A, Hansen L, Dossus L, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. Br J Cancer. 2015;5. doi: 10.1038/bjc.2015.22.
- 10.Shui IM, Mondul AM, Lindström S, Tsilidis KK, Travis RC, Gerke T,et al. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015;2. doi: 10.1002/cncr.29320.
- 15.Aebi S, Castiglione M. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis; treatment and follow-up. Ann Oncol. 2009;20(Supp4):iv21–3.Google Scholar
- 25.Guideline No. 62RCOG/BSGE Joint Guideline Royal College guidelines 2011. Management of suspected ovarian masses in premenopausal women. Green-top.Google Scholar